Deal expands SPI Pharma’s manufacturing footprint in Germany, enhances pharmaceutical ingredient offerings, and reinforces focus on fast-growing digestive health market
The launch comes against the backdrop of a significant public health burden
Initiative focuses on early diagnosis, gut health awareness and long-term gluten-free care for children with celiac disease
The precision health platform integrates genetics, biomarkers, diet, and lifestyle data to deliver personalised gut health interventions and therapy support
A brand from Opella will be part of the official NASA astronaut formulary
This study evaluated a difficult-to-treat Crohn's disease patient population
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
The lab will facilitate the development of herbal and natural-based solutions
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA before special items decreases to €4.08 billion (7.4%)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
